Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
IQVIA Holdings Inc is a diagnostics & research business based in the US. IQVIA shares (IQV) are listed on the NYSE and all prices are listed in US Dollars. IQVIA employs 74,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$262.27|
|52-week range||$146.00 - $265.34|
|50-day moving average||$255.18|
|200-day moving average||$232.41|
|Wall St. target price||$278.16|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$3.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||2.32%|
|1 month (2021-08-24)||2.11%|
|3 months (2021-06-24)||8.88%|
|6 months (2021-03-24)||40.92%|
|1 year (2020-09-24)||77.13%|
|2 years (2019-09-24)||68.75%|
|3 years (2018-09-24)||104.01%|
|5 years (2016-09-23)||230.27%|
Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IQVIA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 82x. In other words, IQVIA shares trade at around 82x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IQVIA's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.105. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IQVIA's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IQVIA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.2 billion.
The EBITDA is a measure of a IQVIA's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$12.9 billion|
|Operating margin TTM||9.02%|
|Gross profit TTM||$3.9 billion|
|Return on assets TTM||3.09%|
|Return on equity TTM||10.85%|
|Market capitalisation||$49 billion|
TTM: trailing 12 months
There are currently 3.0 million IQVIA shares held short by investors – that's known as IQVIA's "short interest". This figure is 22.8% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting IQVIA shares can be evaluated.
IQVIA's "short interest ratio" (SIR) is the quantity of IQVIA shares currently shorted divided by the average quantity of IQVIA shares traded daily (recently around 625750.31185031). IQVIA's SIR currently stands at 4.81. In other words for every 100,000 IQVIA shares traded daily on the market, roughly 4810 shares are currently held short.
However IQVIA's short interest can also be evaluated against the total number of IQVIA shares, or, against the total number of tradable IQVIA shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IQVIA's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 IQVIA shares in existence, roughly 20 shares are currently held short) or 0.0158% of the tradable shares (for every 100,000 tradable IQVIA shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IQVIA.
Find out more about how you can short IQVIA stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IQVIA.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.81
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IQVIA's overall score of 26.81 (as at 12/31/2018) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IQVIA is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.17/100
IQVIA's environmental score of 1.17 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.76/100
IQVIA's social score of 14.76 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 6.88/100
IQVIA's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that IQVIA is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. IQVIA scored a 1 out of 5 for controversy – the highest score possible, reflecting that IQVIA has managed to keep its nose clean.
|Total ESG score||26.81|
|Total ESG percentile||36.72|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||1|
We're not expecting IQVIA to pay a dividend over the next 12 months.
Over the last 12 months, IQVIA's shares have ranged in value from as little as $146 up to $265.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.4214. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.